Suggestions
Dan Robinson
Wrangling complexity to advance human and planetary health.
Professional Background
Dan Robinson is a highly regarded venture capitalist and thought leader in the intersection of computation and hard sciences, with extensive experience in supporting innovative companies that harness the power of technology to transform industries and tackle global challenges. As a key figure at the OS Fund, Dan plays an essential role in identifying and investing in seed through Series B stage ventures with visionary goals, particularly in the realms of synthetic biology, computational biology, materials science, robotics, and advanced manufacturing and industrial automation. With an impressive portfolio of over 30 companies across the U.S., Canada, and the UK, the OS Fund under Dan's stewardship fosters extraordinary innovations that promise a brighter, more sustainable future.
Prior to his influential role at the OS Fund, Dan’s career spanned various prominent organizations where he made significant contributions as an investor and strategist. His notable positions include serving as a Series A Investor at Parthenon Therapeutics and as a Venture Partner at KdT Ventures, along with investment roles at companies like Truvian, GRO Biosciences, and NuMat Technologies. His deep insights into venture capital have positioned him as a sought-after advisor in the startup ecosystem, where he leverages his expertise to guide budding entrepreneurs and technical innovators.
Through his work with the OS Fund and amongst various prior roles, Dan Robinson has proven himself to be a master at recognizing emerging technologies and the transformative potential they hold. His commitment to innovation not only includes financial investments but also hands-on involvement in portfolio companies, maximizing their trajectory toward success.
Education and Achievements
Dan Robinson’s educational background is a testament to his commitment to both the sciences and business. He holds a Bachelor of Arts degree in History, Economics, and Biology from Dartmouth College, which laid the foundational knowledge for his multifaceted career in science and economics. Dan further expanded his intellectual horizons by studying Philosophy, Politics, and Economics at the prestigious University of Oxford, refining his critical thinking and analytical skills, which are invaluable in the world of venture capital.
To complement his undergraduate academic pursuits, Dan earned a Master of Business Administration (MBA) with a focus on Entrepreneurial Management from the Wharton School at the University of Pennsylvania. This advanced degree equipped him with essential business acumen and managerial expertise, empowering him to navigate the complexities of investment and corporate strategy effectively.
Notable Investments
Throughout his career, Dan has made a significant impact through various investments and strategic partnerships. At OS Fund, he has been instrumental in nurturing promising companies that utilize cutting-edge technologies in synthetic biology and robotics to create substantial value and solve pressing challenges in society. His past roles as a Series A Investor in Parthenon Therapeutics and Truvian highlight his ability to recognize potential and drive growth in healthcare and life sciences.
Dan’s time as a Venture Partner at KdT Ventures saw him explore unique market opportunities and engage with forward-thinking entrepreneurs, thereby amplifying the reach and influence of innovative technologies and business models. His dedication to early-stage investment shines through his involvement with companies like A-Alpha Bio and GRO Biosciences, where he provided not only capital but also strategic guidance that propelled these organizations toward aggressive scaling.
Continuously pushing the boundaries of venture capital, Dan has been enthusiastic about sectors that combine science and technology, ensuring that his investments at OS Fund span a diverse range of transformative fields. He is dedicated to fostering collaboration among startups, investors, and academic institutions, believing that innovation is best achieved through interdisciplinary efforts and partnerships.
Conclusion
In conclusion, Dan Robinson embodies the spirit of innovation and strategic thinking that the venture capital industry thrives upon. With a formidable educational background and a wealth of experience in technology investing and startup advisory roles, he stands at the forefront of emerging scientific technologies and their potential impact on industries as well as society at large. His work at OS Fund continues to pave the way for groundbreaking advancements that will undoubtedly shape the future in remarkable ways. Dan Robinson is not just an investor; he is a visionary who believes in the power of science and technology to create a better tomorrow.
Highlights

